- New Board Appointment Deepens and Solidifies Servatus’ Extensive Business and Scientific Expertise for its Global Biotherapeutics Programs
- Dr Buecheler joins as non-executive director of pharmaceutical giant Boehringer Ingelheim in Germanywhere he is both Senior Vice President and Senior Biopharmaceutical Advisor to the Board of Directors
- +30 years at Boehringer Ingelheim, he leads the biopharmaceutical activity in Germany, Austria and the United States, and recently developed a new site in Shanghai, China
- Is responsible for major expansion projects, 30+ Biologics Approvals/Launches and 5+ Global Top 20 Biopharmaceuticals
- This this appointment will accelerate Servatus’ unique drug discovery and development programs.
SYDNEY, May 2, 2022 /PRNewswire/ — Servatus Limited, an Australian biopharmaceutical company providing novel autoimmune and microbiome therapies, is pleased to announce the appointment of Dr. Uwe Bucheler to its board of directors as a non-executive director. Dr. Buecheler is a leading molecular biologist with over 30 years of biopharmaceutical experience at Boehringer Ingelheim in Germany. Boehringer Ingelheim is one of the world’s leading pharmaceutical companies and the largest private pharmaceutical company, with annual revenues exceeding $17 billion and more than 50,000 employees.
Doctor At Uwe Buecheler’s this appointment brings significant commercial and scientific experience to the Servatus Board of Directors at a time when the company is strengthening its Australian research and development capabilities for market-leading live biotherapeutic programs, including clinical trials for IBS- C, insomnia, rheumatoid arthritis and other health problems associated with the gut-microbiome-brain axis.
Dr. Buecheler is Senior Biopharmaceutical Advisor to the Boehringer Ingelheim Board of Directors, having joined the company in 1991. While at Boehringer Ingelheim, Dr. Buecheler held various leadership positions in CMC development, regulatory , biosafety, quality and as site manager and responsible for the expansion of Boehringer Ingelheim’s global operating network in Europethe United States and China. He threw 1st MAH approval in Shanghai and played a key role in major expansion projects in aseptic processing, microbial manufacturing and large-scale mammalian cell culture operations. Dr. Buecheler has overseen more than 30 biologics approvals/launch, including more than five of the top 20 global biopharmaceuticals.
Doctor wayne finlaysonCEO of Servatus commented, “We are delighted to have Dr. Uwe Bucheler join our board of directors as a non-executive director. Uwe brings extensive scientific and commercial leadership as well as invaluable experience in developing global biopharmaceutical operations. His appointment will significantly enhance the capabilities of our Board of Directors and further complement the high-calibre team that Servatus has built around the world as we seek to advance the development of our market-leading biotherapeutic programs. We hope to leverage Uwe’s extensive knowledge and experience acquired during his many years at Boehringer Ingelheim, one of the world’s largest pharmaceutical companies, while expanding Servatus’ core business units over the next three coming years. »
Doctor Uwe Bucheler said: “I am delighted to join the Servatus Board of Directors during an exciting period of growth for the company. Servatus is supported by a highly experienced and credible team who are at the forefront of microbial biotherapy and c t is an honor for me to take this opportunity to help contribute to the growth of Servatus at a pivotal time in the company’s history. I look forward to achieving our goals of maximizing the capabilities of global expansion of this leading company over the next three years and beyond.
Dr. Buecheler obtained his doctorate in molecular biology at the University of Heidelberg and the Cancer Research Center in Heidelberg. He was appointed hc professor at the University of Ulm and is a member of the advisory boards of the university and of the Society for Biochemistry and Molecular Biology (GBM). Furthermore, he is chairman of the Biopharma Cluster South Germany and is a member of several biopharmaceutical industry associations, including the international leadership forum ISPE.
About Servatus | www.servatus.com.au
Founded in 2012, Servatus Ltd is an Australian biopharmaceutical company dedicated to creating safe, effective and reliable microbiome-based therapeutic drugs to treat several chronic and debilitating autoimmune diseases, as well as non-antibiotic treatments for bacterial infections. . In addition to our research and development of innovative drugs and ongoing clinical trials, Servatus also has a state-of-the-art production facility. Our own production facility means Servatus is able to oversee all aspects of the research development and production pipeline and ensure that our live microbial biotherapeutic drug candidates are manufactured to our high standards and specifications, eliminating the logistical uncertainty often associated with outsourcing manufacturing. Servatus is an unlisted public company headquartered in Coolum, queensland. The Society takes its name from St Servatus who was a clergyman and diplomat in the 4th century and became Bishop of Tongeren, a city and municipality today Belgium. Servatus has been invoked by Catholics as a patron saint, with healing powers for a range of ailments, including rheumatism.
About Live Biotherapeutics
One of Servatus’ main areas of research is the development of living biotherapeutic products (live microorganisms) that can be used to prevent or treat disease. Historically, the application of selected bacterial strains has been dedicated to modulating and repairing the gut microbiome. However, Servatus’ research focuses on the development of living biotherapeutics applicable to the prevention, treatment or cure of specific diseases or conditions in humans. Servatus targets autoimmune and inflammatory conditions associated with dysbiosis and immune dysregulation, including ulcerative colitis, arthritis, atopic dermatitis, and infections of the gastrointestinal and urogenital tracts. Servatus uses bacterial strains that have not been widely used before. They have demonstrated bioactive properties that inhibit pathogenic bacterial growth and infection, modulate immune responses, and regulate inflammatory signals. The effectiveness of bacterial strains is due to their cell surface structures and, above all, to the biological effector molecules they secrete, which interact and communicate with the body’s own cells. The bacterial candidates are being developed to act directly on specific sites in the gastrointestinal tract and on targeted organ sites that are influenced by microbial interactions.